Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C23H29N3O2S
Monoisotopic mass
411.198047877
InChI
InChI=1S/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3
InChI Key
InChIKey=WNTYBHLDCKXEOT-UHFFFAOYSA-N
IUPAC Name
1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)ethan-1-one
Traditional IUPAC Name
acetophenazine
SMILES
CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1
pKa (strongest acidic)
15.46
pKa (Strongest Basic)
8.07
Refractivity
121.7 m3·mol-1
Dược Lực Học :
Acetophenzine is a phenothiazine antipsychotic intended for the management of schizophrenia and other psychotic disorders.
Cơ Chế Tác Dụng :
Acetophenazine is an antipsychotic drug of moderate-potency. It is used in the treatment of disorganized and psychotic thinking. It is also used to help treat false perceptions (e.g. hallucinations or delusions). It primarily targets the dopamine D2 receptor.
Acetophenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Chỉ Định :
For the treatment of disorganized and psychotic thinking. Also used to help treat false perceptions (e.g. hallucinations or delusions.)
Tương Tác Thuốc :
-
Bromocriptine
The phenothiazine decreases the effect of bromocriptine
-
Cisapride
Increased risk of cardiotoxicity and arrhythmias
-
Dexfenfluramine
Decreased anorexic effect, may increase psychotic symptoms
-
Diethylpropion
Decreased anorexic effect, may increase psychotic symptoms
-
Fenfluramine
Decreased anorexic effect, may increase psychotic symptoms
-
Guanethidine
Acetophenazine may decrease the effect of guanethidine.
-
Mazindol
Decreased anorexic effect, may increase psychotic symptoms
-
Phentermine
Decreased anorexic effect, may increase psychotic symptoms
-
Phenylpropanolamine
Decreased anorexic effect, may increase psychotic symptoms
-
Tacrine
The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Acetophenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
-
Terfenadine
Increased risk of cardiotoxicity and arrhythmias
-
Tetrabenazine
May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
-
Trimethobenzamide
Trimethobenzamide and Acetophenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
-
Triprolidine
The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Acetophenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
-
Trospium
Trospium and Acetophenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.